Corteria Pharmaceuticals

Corteria Pharmaceuticals is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2021.

The company is dedicated to developing first-in-class therapies for patient subpopulations with high unmet medical needs, particularly in heart failure, sarcopenia, and obesity with complications. Corteria focuses on stratifying patients to match them with therapies that are most likely to benefit them, translating disease biology into targeted treatments. The company specializes in drug discovery and clinical development, with a pipeline that includes investigational therapies such as COR-1167, a CRF2 agonist for worsening heart failure, and COR-2007, a monoclonal antibody for acute heart failure with hyponatremia. Corteria is a spin-out from Sanofi and has raised significant venture funding, including a Series A round of approximately $71 million. Its business model primarily targets medical professionals, clinical collaborators, research partners, and investors.